JP6890340B6 - グルカゴン受容体アンタゴニスト抗体を用いた心不全の治療法 - Google Patents

グルカゴン受容体アンタゴニスト抗体を用いた心不全の治療法 Download PDF

Info

Publication number
JP6890340B6
JP6890340B6 JP2018511277A JP2018511277A JP6890340B6 JP 6890340 B6 JP6890340 B6 JP 6890340B6 JP 2018511277 A JP2018511277 A JP 2018511277A JP 2018511277 A JP2018511277 A JP 2018511277A JP 6890340 B6 JP6890340 B6 JP 6890340B6
Authority
JP
Japan
Prior art keywords
body weight
antibody
seq
amino acid
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018511277A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018528210A (ja
JP6890340B2 (ja
JP2018528210A5 (cg-RX-API-DMAC7.html
Inventor
ヤン,ハイ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Remd Biotherapeutics Inc
Original Assignee
Remd Biotherapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Remd Biotherapeutics Inc filed Critical Remd Biotherapeutics Inc
Publication of JP2018528210A publication Critical patent/JP2018528210A/ja
Publication of JP2018528210A5 publication Critical patent/JP2018528210A5/ja
Publication of JP6890340B2 publication Critical patent/JP6890340B2/ja
Application granted granted Critical
Publication of JP6890340B6 publication Critical patent/JP6890340B6/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2869—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/68—Plantaginaceae (Plantain Family)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Cardiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
JP2018511277A 2015-09-04 2016-09-02 グルカゴン受容体アンタゴニスト抗体を用いた心不全の治療法 Active JP6890340B6 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562214449P 2015-09-04 2015-09-04
US62/214,449 2015-09-04
US201562259061P 2015-11-24 2015-11-24
US62/259,061 2015-11-24
PCT/US2016/050183 WO2017040986A1 (en) 2015-09-04 2016-09-02 Methods for treating heart failure using glucagon receptor antagonistic antibodies

Publications (4)

Publication Number Publication Date
JP2018528210A JP2018528210A (ja) 2018-09-27
JP2018528210A5 JP2018528210A5 (cg-RX-API-DMAC7.html) 2019-11-28
JP6890340B2 JP6890340B2 (ja) 2021-06-18
JP6890340B6 true JP6890340B6 (ja) 2021-07-14

Family

ID=58188491

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018511277A Active JP6890340B6 (ja) 2015-09-04 2016-09-02 グルカゴン受容体アンタゴニスト抗体を用いた心不全の治療法

Country Status (7)

Country Link
US (2) US10765737B2 (cg-RX-API-DMAC7.html)
EP (1) EP3344279B1 (cg-RX-API-DMAC7.html)
JP (1) JP6890340B6 (cg-RX-API-DMAC7.html)
CN (1) CN108348582B (cg-RX-API-DMAC7.html)
AU (1) AU2016318097B2 (cg-RX-API-DMAC7.html)
CA (1) CA2999747A1 (cg-RX-API-DMAC7.html)
WO (1) WO2017040986A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7005638B2 (ja) 2017-01-27 2022-02-04 エヌジーエム バイオファーマシューティカルス,インコーポレーテッド グルカゴン受容体結合タンパク質及びその使用方法
EP3829636A1 (en) 2018-07-27 2021-06-09 NGM Biopharmaceuticals, Inc. Use of glucagon receptor antagonists with immunotherapeutic agent
JP7840511B2 (ja) 2019-02-01 2026-04-06 石▲薬▼集▲団▼巨石生物制▲薬▼有限公司 抗クローディン18抗体及びそれらの使用の方法
CN118393150B (zh) * 2024-06-27 2024-09-13 潍坊市润生畜禽良种有限公司 一种优化gcgr卵黄抗体制备的方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030103983A1 (en) 2002-05-09 2003-06-05 Pressler Milton Lethan Ace inhibitor-vasopressin antagonist combinations
WO2006005469A2 (en) 2004-07-15 2006-01-19 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with glucagon receptor (gcgr)
CL2007002668A1 (es) * 2006-09-20 2008-05-09 Amgen Inc Proteina de union a antigeno que se une al receptor de glucagon humano; acido nucleico que la codifica; metodo de produccion; composicion farmaceutica que la comprende; y su uso para tratar o prevenir la diabetes tipo 2.
US9034883B2 (en) * 2010-11-15 2015-05-19 Boehringer Ingelheim International Gmbh Vasoprotective and cardioprotective antidiabetic therapy
US8771696B2 (en) 2010-11-23 2014-07-08 Regeneron Pharmaceuticals, Inc. Method of reducing the severity of stress hyperglycemia with human antibodies to the glucagon receptor

Also Published As

Publication number Publication date
US20200353079A1 (en) 2020-11-12
US11446376B2 (en) 2022-09-20
CN108348582B (zh) 2023-04-14
JP2018528210A (ja) 2018-09-27
AU2016318097B2 (en) 2023-04-20
AU2016318097A1 (en) 2018-04-12
CA2999747A1 (en) 2017-03-09
WO2017040986A1 (en) 2017-03-09
EP3344279A1 (en) 2018-07-11
US20180256713A1 (en) 2018-09-13
US10765737B2 (en) 2020-09-08
CN108348582A (zh) 2018-07-31
JP6890340B2 (ja) 2021-06-18
EP3344279A4 (en) 2019-03-27
EP3344279B1 (en) 2020-07-15

Similar Documents

Publication Publication Date Title
US12534503B2 (en) Mutant fibroblast growth factor 21 (FGF21) polypeptides
US11446376B2 (en) Methods for treating heart failure using glucagon receptor antagonistic antibodies
JP6861641B2 (ja) グルカゴン受容体アンタゴニスト抗体を用いた肥満症および非アルコール性脂肪性肝疾患または非アルコール性脂肪性肝炎を治療するための方法
US20230075314A1 (en) VECTORIZED ANTIBODIES (vAb) AND USES THEREOF
KR102442984B1 (ko) 글루카곤 수용체 길항 항체를 이용한 제 1 형 당뇨병의 치료 방법
KR102701695B1 (ko) 항-dkk-1 항체를 사용하여 암을 치료하기 위한 바이오마커로서의 베타-카테닌의 용도
CN102171240A (zh) 治疗炎症的方法
KR20210132232A (ko) Il-4r 길항제를 투여함에 의한 비용종증의 치료 방법
MXPA05012497A (es) Composiciones y metodos para el tratamiento del sindrome respiratorio agudo severo (sars).
TW201113036A (en) Method of treating cancer with Dll4 antagonist and chemotherapeutic agent
UA129672C2 (uk) Антитіло до trem-1 та його застосування
WO2012135868A2 (en) Compositions and methods for the treatment and prevention of cardiac ischemic injury
KR20220131223A (ko) Dkk-1 억제제를 사용하여 암을 치료하는 방법
WO2011116245A2 (en) Methods of treating inflammation
CN115279393A (zh) 以介白素24或介白素20拮抗剂治疗组织纤维化和/或损伤和/或器官衰竭

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190830

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190830

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191016

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200901

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201201

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210420

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210518

R150 Certificate of patent or registration of utility model

Ref document number: 6890340

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R154 Certificate of patent or utility model (reissue)

Free format text: JAPANESE INTERMEDIATE CODE: R154

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250